Exelixis set a March 3, 2027 PDUFA for zanza and advanced Wave 2 pivotal plans.
Context
What happened: Exelixis outlined a March 3, 2027 PDUFA date for zanzalintinib while advancing Wave 2 pivotal plans, per its Q3 2026 earnings call.
Key numbers: PDUFA date March 3, 2027.
Why it matters: Management framed zanzalintinib as the company's second franchise molecule and the next growth driver, with continued expansion beyond current pivotal work.
What changed
Exelixis outlined a March 3, 2027 PDUFA date for zanzalintinib while advancing Wave 2 pivotal plans, per its Q3 2026 earnings call.